A Glance into MTHFR Deficiency at a Molecular Level

Autor: Castrense Savojardo, Giulia Babbi, Davide Baldazzi, Pier Luigi Martelli, Rita Casadio

Publikováno v: International Journal of Molecular Sciences, Vol 23, Iss 167, p 167 (2022)
International Journal of Molecular Sciences; Volume 23; Issue 1; Pages: 167
International Journal of Molecular Sciences

MTHFR deficiency still deserves an investigation to associate the phenotype to protein structure variations. To this aim, considering the MTHFR wild type protein structure, with a catalytic and a regulatory domain and taking advantage of state-of-the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a387455535e21b688b2c0c6749dd55d
https://www.mdpi.com/1422-0067/23/1/167

Systematic screening of CTCF binding partners identifies that BHLHE40 regulates CTCF genome-wide distribution and long-range chromatin interactions

Autor: Yawei Song, Gongcheng Hu, Xiaotao Dong, Shixin Gong, Andrew P. Hutchins, Hongjie Yao

Publikováno v: Nucleic Acids Research

CTCF plays a pivotal role in mediating chromatin interactions, but it does not do so alone. A number of factors have been reported to co-localize with CTCF and regulate CTCF loops, but no comprehensive analysis of binding partners has been performed.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5285d5546563507bdbce0d3c757b001
https://doi.org/10.1093/nar/gkaa705

Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib

Autor: Isabella Pallavicini, Greta Bagnolini, Andrea Balboni, Marinella Roberti, Janet Robertson, Giuseppina Di Stefano, Fulvia Farabegoli, Sebastiano Peri, Jose Antonio Ortega, Saverio Minucci, D. Gioia, Federico Falchi, Domenico Milano, Francesca De Franco, Fabrizio Schipani, Roberto Pellicciari, Andrea Cavalli, Marcella Manerba, Stefania Girotto

Publikováno v: Journal of Medicinal Chemistry

Synthetic lethality is an innovative framework for discovering novel anticancer drug candidates. One example is the use of PARP inhibitors (PARPi) in oncology patients with BRCA mutations. Here, we exploit a new paradigm based on the possibility of t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56a9ce8f1a24b0337c5b7b86be9e4f0a
https://doi.org/10.1021/acs.jmedchem.9b01526

A protein interaction landscape of breast cancer

Autor: Danielle L. Swaney, Kuei Ho Chen, Alan Ashworth, Morgan E. Diolaiti, Trey Ideker, Fan Zheng, Bing Xia, Kari A. Herrington, Beril Tutuncuoglu, Michael J. McGregor, John D. Gordan, Min-Kyu Kim, Mehdi Bouhaddou, Denise P. Muñoz, Denise M. Wolf, Erica Stevenson, Nevan J. Krogan, Margaret Soucheray, Tzeh Keong Foo, Patrick O’Leary, Ajda Rojc, Maya Modak, Kyumin Kim, Laura van 't Veer, Jean-Philippe Coppe, Jason F. Kreisberg, Jisoo Park, Dominique C. Mitchell

Publikováno v: Science
Science (New York, N.Y.), vol 374, iss 6563

Mapping protein interactions driving cancer Cancer is a genetic disease, and much cancer research is focused on identifying carcinogenic mutations and determining how they relate to disease progression. Three papers demonstrate how mutations are proc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::375ba5ac99a6a028e92c535730897988
https://europepmc.org/articles/PMC9040556/

Protein interaction networks revealed by proteome coevolution

Autor: Qian Cong, David Baker, Ivan Anishchenko, Sergey Ovchinnikov

Publikováno v: Science. 365:185-189

Residue-residue coevolution has been observed across a number of protein-protein interfaces, but the extent of residue coevolution between protein families on the whole-proteome scale has not been systematically studied. We investigate coevolution be

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13859c8f54f5c0e44ea9afa35fc76994
https://doi.org/10.1126/science.aaw6718